These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis. Amin N, Dozor AJ. Pediatr Pulmonol; 1994 Sep; 18(3):150-4. PubMed ID: 7800431 [Abstract] [Full Text] [Related]
8. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Suri R, Metcalfe C, Wallis C, Bush A. Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126 [Abstract] [Full Text] [Related]
9. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. N Engl J Med; 1994 Sep 08; 331(10):637-42. PubMed ID: 7503821 [Abstract] [Full Text] [Related]
10. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group. Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, Heijerman HG, FitzGerald MX, Richard D, Strandvik B, Kolbe J, Kraemer R, Michalsen H. Pediatr Pulmonol; 1998 Sep 08; 26(3):155-61. PubMed ID: 9773909 [Abstract] [Full Text] [Related]
17. [Clinical development of rhDNase in the United States]. Eisenberg J. Arch Pediatr; 1995 Jul 08; 2(7):674-8. PubMed ID: 7663659 [Abstract] [Full Text] [Related]